This brand name is authorized in Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa
The drug ZIAGEN contains one active pharmaceutical ingredient (API):
1
Abacavir
UNII J220T4J9Q2 - ABACAVIR SULFATE
|
Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
ZIAGEN Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZIAGEN Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
J05AF06 | Abacavir | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 10294T, 10356C |
Country: CA | Health Products and Food Branch | Identifier(s): 02240357, 02240358 |
Country: EE | Ravimiamet | Identifier(s): 1196119, 1196120 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 99112001, 99112002 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 101995, 102006 |
Country: FR | Base de données publique des médicaments | Identifier(s): 62070450, 68556562 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 44427, 44430 |
Country: HK | Department of Health Drug Office | Identifier(s): 46236, 63701 |
Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 4210 |
Country: IT | Agenzia del Farmaco | Identifier(s): 034499018, 034499020 |
Country: JP | 医薬品医療機器総合機構 | Identifier(s): 6250014F1036 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1006256, 1006257 |
Country: NL | Z-Index G-Standaard | Identifier(s): 14255782 |
Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 135992, 136018 |
Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 8479, 8480 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100095210, 100095227 |
Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W65271001, W65272001 |
Country: SG | Health Sciences Authority | Identifier(s): 11098P |
Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 23013041H |
Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699522096107 |
Country: US | FDA, National Drug Code | Identifier(s): 49702-221, 49702-222 |
Country: ZA | Health Products Regulatory Authority | Identifier(s): 33/20.2.8/0464, 33/20.2.8/0465 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.